#USA #Mountain View #Turn Biotechnologies #ERA™ Therapy #Bone Marrow

Turn Biotechnologies Unveils Landmark Study on ERA™ Therapy

Turn Biotechnologies, renowned for its innovative approaches in cell rejuvenation and restoration, has announced a pivotal study aimed at evaluating the effectiveness of its epigenetic reprogramming technology, ERA™ therapy, in restoring aging bone marrow. Conducted in collaboration with the Children's Hospital of Philadelphia (CHOP) and financially backed by the Methuselah Foundation, this study is set to revolutionize the future of stem cell transplantation.

Understanding the Need for Innovation in Bone Marrow Treatments

As individuals age, their bone marrow's ability to produce crucial blood cells and immune responses diminishes. This decline leads to an increased risk of diseases as the body becomes less efficient at combating infection and healing. Furthermore, aged bone marrows collect DNA changes termed clonal hematopoiesis, which can result in serious conditions such as leukemia. Recognizing these challenges, the study seeks to rejuvenate donor stem cells, potentially improving transplant efficacy and safety.

Dr. Timothy Olson, the principal investigator and Medical Director of the Blood and Marrow Transplant section at CHOP, emphasizes the significant advantages of utilizing younger donor cells. Research has demonstrated that patients receiving stem cells from younger donors often experience superior clinical outcomes. The goal of this study is to harness epigenetic reprogramming to make bone marrow transplants not just more effective, but also more accessible, thus transcending age barriers for donors.

The Approach: ERA™ Therapy

The study will utilize Turn Biotechnologies' unique ERA™ therapy, which employs mRNA technology aimed at resetting the gene expression profile within aged cells. This innovative treatment is expected to restore the function and performance of older stem cells, effectively allowing them to regain their youthful capabilities. By rejuvenating these cells, researchers hope to enhance the body's immune response, expedite wound healing, and improve overall health outcomes for transplant recipients.

CEO of Methuselah Foundation, David Gobel, predicts that the findings will confirm the regenerative properties of epigenetic reprogramming, potentially extending the healthy human lifespan through advanced therapeutic modalities. The study will monitor the effects of the ERA™ therapy on mouse blood progenitor cells, followed by their transplantation into irradiated mice of comparable genetic backgrounds.

A Year of Exploration

Set to span one year, the research represents a critical milestone for Turn Biotechnologies, illustrating their commitment to advancing the scientific understanding of cell rejuvenation beyond singular therapeutic applications. Anja Krammer, CEO of Turn Biotechnologies, voiced optimism about the study’s potential, reiterating the pre-clinical evidence supporting the safety and effectiveness of their ERA treatments in human cells.

This landmark study symbolizes a significant stride towards harnessing epigenetic strategies to not only address specific medical challenges but to enhance the collective healthspan of individuals globally. With ongoing developments in personalized therapeutics, the implications of this research could change perceptions and paradigms surrounding age-related medical care.

About Turn Biotechnologies

Turn Biotechnologies operates at the forefront of biotechnological advancement with a focus on cellular rejuvenation. Their flagship mRNA-based ERA™ technology aims to combat the biological effects of aging by restoring essential gene expressions. Furthermore, their innovative eTurna™ Delivery Platform is designed to ensure precise delivery of therapeutic cargo to targeted tissues, which could transition the landscape of medical treatments for chronic diseases.

For more insights about Turn Biotechnologies and their ongoing projects, please visit their official page at turn.bio.